The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -8,198 |
| Amortization of debt discount | 820 |
| Amortization of patents | 262 |
| Depreciation and amortization | 1,234 |
| Amortization of right-of-use asset | 135 |
| Write off of inventory | 253 |
| Bad debt expense | 40 |
| Loss on abandoned patents | 559 |
| Write off of fixed assets | 104 |
| Foreign currency transaction (gains) losses | 9,321 |
| Stock-based compensation | 2,765 |
| Grants and accounts receivable | -423 |
| Inventories | 2,540 |
| Prepaid expenses and other current assets | -1,791 |
| Other assets | -2 |
| Accounts payable and accrued expenses | -706 |
| Net cash used in operating activities | -12,377 |
| Purchases of property and equipment | 164 |
| Disposal of property and equipment | 76 |
| Patent costs | 327 |
| Net cash used in investing activities | -415 |
| Proceeds from long-term debt | 2,478 |
| Proceeds from rights offering, net | 5,392 |
| Cash for exercise of warrants, net | 1,439 |
| Net cash provided by financing activities | 9,309 |
| Effect of exchange rates on cash | 1,490 |
| Net change in cash, cash equivalents, and restricted cash | -1,993 |
| Cash, cash equivalents, and restricted cash at beginning of year | 9,764 |
| Cash, cash equivalents, and restricted cash at end of year | 7,771 |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)